 |
29 Diseases |  |
1 Trial |
|
1 Trial |  |
377 News |  |
| «1234 |
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 6, 2017
P2, N=37, Terminated, Sponsor: MedImmune LLC
N=76 --> 37
- ||||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment closed, Metastases: PLAIT: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (clinicaltrials.gov) - Jul 11, 2016
P3, N=77, Active, not recruiting, Sponsor: MedImmune LLC
N=76 --> 37 Recruiting --> Active, not recruiting
- | Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial termination, Trial primary completion date: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma (clinicaltrials.gov) - Nov 21, 2015
P2, N=76, Terminated, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Nov 2015; The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment closed: Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Sep 25, 2015
P1/2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Nov 2015; The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled. Recruiting --> Active, not recruiting
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change, Trial termination, IO biomarker, Minimal residual disease: Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Sep 16, 2015
P2, N=1, Terminated, Sponsor: Center for International Blood and Marrow Transplant Research
Recruiting --> Active, not recruiting N=30 --> 1 | Suspended --> Terminated
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial completion, IO biomarker: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Jul 10, 2015
P1, N=49, Completed, Sponsor: MedImmune LLC
N=30 --> 1 | Suspended --> Terminated Active, not recruiting --> Completed
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial suspension, IO biomarker, Minimal residual disease: Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 15, 2015
P2, N=30, Suspended, Sponsor: Center for International Blood and Marrow Transplant Research
Active, not recruiting --> Completed Recruiting --> Suspended
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial completion, Trial primary completion date: CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 20, 2015
P1, N=58, Completed, Sponsor: MedImmune LLC
Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2014
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial initiation date, Trial primary completion date: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma (clinicaltrials.gov) - May 7, 2015
P2, N=76, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2014 Initiation date: Jan 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Jun 2016
- | Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment open, IO biomarker, Minimal residual disease: Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - May 6, 2015
P2, N=30, Recruiting, Sponsor: Center for International Blood and Marrow Transplant Research
Initiation date: Jan 2014 --> Aug 2014 | Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial initiation date: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 10, 2015
P2, N=76, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Initiation date: Aug 2014 --> Jan 2014
- | Lumoxiti (moxetumomab pasudotox) / AstraZeneca
New P2 trial, IO biomarker, Minimal residual disease: Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 15, 2015
P2, N=30, Not yet recruiting, Sponsor: Center for International Blood and Marrow Transplant Research
- || Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change, Trial primary completion date: CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2015
P1, N=55, Active, not recruiting, Sponsor: MedImmune LLC
Initiation date: Aug 2014 --> Jan 2014 N=76 --> 55 | Trial primary completion date: Apr 2017 --> Mar 2015
- ||||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
New P2 trial: Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 27, 2014
P2, N=76, Recruiting, Sponsor: MedImmune LLC
- || Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment closed, Enrollment change, Trial primary completion date: CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 26, 2014
P1, N=76, Active, not recruiting, Sponsor: MedImmune LLC
N=76 --> 55 | Trial primary completion date: Apr 2017 --> Mar 2015 Recruiting --> Active, not recruiting | N=52 --> 76 | Trial primary completion date: Sep 2014 --> Apr 2017
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial primary completion date, IO biomarker: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Jul 26, 2014
P1, N=50, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | N=52 --> 76 | Trial primary completion date: Sep 2014 --> Apr 2017 Trial primary completion date: Aug 2014 --> Feb 2015
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change, IO biomarker: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Apr 13, 2014
P1, N=50, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Aug 2014 --> Feb 2015 N=63 --> 50
- |||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment open: Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Dec 16, 2013
P1/2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=63 --> 50 Not yet recruiting --> Recruiting
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment closed, IO biomarker: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Nov 10, 2013
P1, N=50, Active, not recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change: CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 2, 2013
P1, N=52, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting N=76 --> 52
- ||||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
New P1/2 trial: Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial completion, Metastases: Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) (clinicaltrials.gov) - May 20, 2013
P1/2, N=87, Completed, Sponsor: MedImmune LLC
N=76 --> 52 Active, not recruiting --> Completed
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial completion: A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 25, 2013
P1/2, N=8, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- || Lumoxiti (moxetumomab pasudotox) / AstraZeneca
New P3 trial, Metastases: PLAIT: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia (clinicaltrials.gov) - Apr 9, 2013
P3, N=80, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change, Metastases: Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) (clinicaltrials.gov) - May 21, 2012
P1/2, N=87, Completed, Sponsor: MedImmune LLC
Suspended --> Completed N=140 --> 87
- ||| Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial initiation date, Metastases: Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) (clinicaltrials.gov) - Mar 29, 2012
P1/2, N=87, Completed, Sponsor: MedImmune LLC
N=140 --> 87 Initiation date: Nov 2009 --> Mar 2010
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial initiation date: A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia (clinicaltrials.gov) - Jan 3, 2012
P1, N=11, Suspended, Sponsor: MedImmune LLC
Initiation date: Nov 2009 --> Mar 2010 Initiation date: Oct 2006 --> Mar 2007
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Enrollment change: A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia (clinicaltrials.gov) - Jan 3, 2012
P1, N=11, Suspended, Sponsor: MedImmune LLC
Initiation date: Oct 2006 --> Mar 2007 N=50 --> 11
- Lumoxiti (moxetumomab pasudotox) / AstraZeneca
Trial initiation date, IO biomarker: A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (clinicaltrials.gov) - Dec 19, 2011
P1, N=50, Active, not recruiting, Sponsor: MedImmune LLC
N=50 --> 11 Initiation date: Aug 2006 --> May 2007